Harbin Medisan Pharmaceutical Co., Ltd (abbreviated
as Harbin Medisan) is a national
high-and-new-tech enterprise
that engages in R&D, manufacturing and
sales of chemical pharmaceutical finished dosage forms and APIs.
It has four wholly owned subsidiaries and one joint stock company, with the
registered capital of 211 million Chinese Yuan. Harbin Medisan owns 13 production lines, with the production capacity of 30 million vials of small
volume injection, 150 million
vials of lyophilized powder for injection, 150 million tablets (capsules) of
solid dosage form, 300 million bottles (bags) of infusion
solution, and 4 metric tons of API. The main
products include: Oxiracetam injection, Alanyl glutamine injection, Cerebroprotein hydrolysate for injection, Ligustrazine hydrochloride for injection, Ossotide for injection, Mirtazapine
tablet, Glucose injection, Sodium chloride injection. The
dosage forms include small volume
Injection, lyophilized powder for injection, solid dosage form, non-PVC soft bag infusion, plastic bottle infusion, glass bottle
infusion and API etc. The...
CN